Minocycline Activity against Unusual Clinically Significant Gram-Negative Pathogens | Zendy

Dee Shortridge | Zendy; S J Ryan Arends | Zendy; Jennifer M Streit | Zendy; Mariana Castanheira | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Minocycline Activity against Unusual Clinically Significant Gram-Negative Pathogens

Author(s) -

Dee Shortridge,

S J Ryan Arends,

Jennifer M Streit,

Mariana Castanheira

Publication year - 2021

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01264-21

Subject(s) - stenotrophomonas maltophilia , burkholderia , microbiology and biotechnology , achromobacter , stenotrophomonas , aeromonas , chryseobacterium , alcaligenes faecalis , alcaligenes , biology , pseudomonas aeruginosa , pseudomonas , bacteria , genetics , 16s ribosomal rna

The minocycline susceptibility of 3,856 isolates including Burkholderia , Achromobacter , Alcaligenes , Aeromonas , and Stenotrophomonas maltophilia from the SENTRY surveillance (2014 to 2019) were analyzed. The susceptibilities of these species (%S) were Achromobacter spp. ( n = 411; 92.6%), Burkholderia cepacia species complex ( n = 199; 85.9%), Aeromonas spp. ( n = 127; 99.2%), Chryseobacterium spp. ( n = 59; 94.9%), Alcaligenes faecalis ( n = 42; 88.1%), and S. maltophilia ( n = 2,287; 99.5%). These data suggest that minocycline is a useful treatment option for infections caused by unusual Gram-negative pathogens.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research